Profil
Bradley Hodges has founded Prothelia, Inc. in 2007, where he holds the title of Chief Scientific Officer.
Currently, he is a Partner at CureDuchenne Ventures LLC since 2022.
Postes actifs de Bradley Hodges
| Sociétés | Poste | Début |
|---|---|---|
Prothelia, Inc.
 Prothelia, Inc. BiotechnologyHealth Technology Prothelia, Inc. operates as a biotechnological company that engages in the provision of protein therapy. It focuses on the treatment of congenital muscular dystrophy type 1A. The company was founded by Bradley Hodges and is headquartered in Milford, MA. | Fondateur | 01/10/2007 |
CureDuchenne Ventures LLC
 CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Private Equity Investor | 01/05/2022 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
CureDuchenne Ventures LLC
CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Finance |
Prothelia, Inc.
Prothelia, Inc. BiotechnologyHealth Technology Prothelia, Inc. operates as a biotechnological company that engages in the provision of protein therapy. It focuses on the treatment of congenital muscular dystrophy type 1A. The company was founded by Bradley Hodges and is headquartered in Milford, MA. | Health Technology |